H.C. Wainwright initiated coverage on Lexicon Pharma with a new price target
$LXRX
Biotechnology: Pharmaceutical Preparations
Health Care
H.C. Wainwright initiated coverage of Lexicon Pharma with a rating of Buy and set a new price target of $10.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/5/2025 | $2.00 → $1.00 | Outperform → Market Perform | Leerink Partners |
| 6/17/2024 | $10.00 | Buy | H.C. Wainwright |
| 4/30/2024 | $5.00 | Outperform | Leerink Partners |
| 3/7/2023 | $3.00 | Hold | Jefferies |
| 8/12/2022 | $10.00 | Overweight | Piper Sandler |
3 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)
3 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)
4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)
THE WOODLANDS, Texas, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced the publication of preclinical data validating Acyl-CoA Synthetase 5 (ACSL5) as a target for obesity and chronic weight management. The paper, titled "Acyl-CoA Synthetase 5 knockout and inhibitors protect against diet-induced obesity in mice by activating the ileal brake," was published online in the Journal of the Endocrine Society. ACSL5 is an enzyme encoded by the Acsl5 gene that plays a vital role in lipid metabolism and is the target of LX9851, the Company's investigational non-incretin, oral, small molecule ACSL5 inhibitor. Animal model data showed that mice geneticall
THE WOODLANDS, Texas, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) announced clinical data on adipose tissue distribution in non-diabetic patients treated with sotagliflozin will be presented at the 22nd Global Cardio Vascular Clinical Trialists Forum (CVCT 2025). The conference is being held December 8-10, 2025, at the Mayflower Hotel in Washington, D.C. This data is from SOTA-P-CARDIA, a prospective, randomized, double-blind, placebo-controlled trial that exclusively enrolled patients with heart failure with preserved ejection fraction (HFpEF) and was conducted by Mount Sinai Medical Center in New York City. "This data, in addition to data recently
THE WOODLANDS, Texas, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that Company management will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3 at 9:00 a.m. ET and at the 8th Annual Evercore Healthcare Conference on Thursday, December 4 at 9:10 a.m. ET. The live events and replays of the presentations can be accessed via the Events page of the Company's website at https://investors.lexpharma.com/. About Lexicon Pharmaceuticals Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients' lives. Through the Genome5000™ program, Lexicon's
Submission status for LEXICON PHARMACEUTICALS INC's drug INPEFA (ORIG-1) with active ingredient SOTAGLIFLOZIN has changed to 'Approval' on 05/26/2023. Application Category: NDA, Application Number: 216203, Application Classification: Type 1 - New Molecular Entity
4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)
4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)
4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)
Leerink Partners downgraded Lexicon Pharma from Outperform to Market Perform and set a new price target of $1.00 from $2.00 previously
H.C. Wainwright initiated coverage of Lexicon Pharma with a rating of Buy and set a new price target of $10.00
Leerink Partners initiated coverage of Lexicon Pharma with a rating of Outperform and set a new price target of $5.00
8-K - LEXICON PHARMACEUTICALS, INC. (0001062822) (Filer)
424B5 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Filer)
8-K - LEXICON PHARMACEUTICALS, INC. (0001062822) (Filer)
THE WOODLANDS, Texas, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced the appointment of Scott Coiante as senior vice president and chief financial officer, effective today, January 2, 2025. Mr. Coiante is a senior finance executive with more than 35 years of experience in the life science and pharmaceutical industries. He joins Lexicon from Agile Therapeutics, where he served as the senior vice president, chief financial officer and treasurer of Agile Therapeutics Inc. from August 2023 to August 2024, as well as from 2011-2019. "I am pleased to join Lexicon at this pivotal moment for the company and eager to contribute to its
THE WOODLANDS, Texas, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that Ivan H. Cheung has been elected to its Board of Directors. Mr. Cheung is a biopharmaceutical executive with more than 25 years of experience in the healthcare industry and a proven track record of shareholder value creation. He is currently the chief executive officer and a director of NextPoint Therapeutics, and he has served as senior advisor to TPG Growth – a growth investing platform within global asset manager TPG – since September 2023. "I am honored to join the Lexicon Board of Directors at this pivotal moment in the company's history, and to support its mis
THE WOODLANDS, Texas, July 08, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that the Lexicon Board of Directors has appointed Mike Exton, Ph.D. as chief executive officer and director of Lexicon. Dr. Exton succeeds Lonnel Coats who, as previously announced, retired effective July 7, 2024. Dr. Exton most recently served as the global cardiometabolic therapeutic head at Novartis. "I am confident that Mike is the right person to serve as Lexicon's next chief executive officer at this critical time for the company," said Ray Debbane, chairman of Lexicon's board of directors. "He is an inspiring leader with a demonstrated track record of success, includi
SC 13D/A - LEXICON PHARMACEUTICALS, INC. (0001062822) (Subject)
SC 13G/A - LEXICON PHARMACEUTICALS, INC. (0001062822) (Subject)
SC 13G/A - LEXICON PHARMACEUTICALS, INC. (0001062822) (Subject)
FDA End-of-Phase 2 meeting for pilavapadin in DPNP to be held by year-end All IND-enabling studies of LX9851 for obesity completed and submitted to licensee Novo Nordisk Site initiation for SONATA-HCM Phase 3 study of sotagliflozin in both obstructive and non-obstructive HCM completed; enrollment completion on target for 2026 Additional data in support of potential resubmission of Zynquista for type 1 diabetes submitted to FDA Conference call and webcast at 8:30 am ET THE WOODLANDS, Texas, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), today reported financial results for the three months ended September 30, 2025, and provided an update on key corpo
THE WOODLANDS, Texas, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced the Company will release its third quarter 2025 financial results on Thursday, November 6, 2025, prior to market open. Management will conduct a conference call and live webcast at 8:30 a.m. ET (7:30 a.m. CT) that day to discuss the financial results and to provide a business update. Participants can access the conference call live via webcast on the Events page of the Company's website at https://investors.lexpharma.com/. Participants who wish to ask a question may register here to receive dial-in numbers and a unique pin to join the call. An archived version of the webcast
Partnership discussions for pilavapadin remain underway following Phase 2b PROGRESS study results IND-enabling studies of LX9851 for obesity and related disorders on track for completion in 2025 with licensee Novo Nordisk expected to submit IND Enrollment completion for SONATA Phase 3 study in both obstructive and non-obstructive hypertrophic cardiomyopathy (HCM) on target for 2026 Conference call and webcast at 8:30 am ET THE WOODLANDS, Texas, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), today reported financial results for the three months ended June 30, 2025, and provided an update on key corporate milestones and accomplishments. "We continue t